Top Story

Medicaid Guidance Aims To Help States Save Money With Biosimilars

CMS released strategies for states to save money with biosimilars Monday (March 30) that include placing biosimilars on preferred drug lists in return for drug companies offering extra rebates.

Latest News

The Supreme Court ruled Tuesday (March 31) that providers can't sue states over Medicaid rates, in part because HHS handles rate setting and the law on rate setting is too broad for federal courts to take up.

A new study finds Medicare Advantage plans serving low income beneficiaries may be providing higher quality care than their star ratings suggest.

The American Hospital Association is fighting against an Affordable Care Act provision they say unfairly penalizes hospitals for readmission of patients.

CMS is asking for feedback on the requirement that qualified health plans (QHPs) publish machine-readable data on provider networks and prescription drug formularies, which will help consumers compare qualified health plans in the federal marketplace.

CMS has delayed implementation of revised summary of benefits and coverage (SBC) templates and now says the updated forms must be used for all coverage as of Jan. 1, 2017, rather than Sept. 15, 2015, but the administration remains “fully committed” to revising the materials as soon as possible, according to a frequently asked questions (FAQ) response generated by HHS, the Treasury Department and the Department of Labor on Monday (March 30).

Maryland's Department of Health and Mental Hygiene mistakenly allocated nearly $30 million to its health insurance exchange that should have gone to the State's Medicaid agency due to problems with the state's cost allocation methodology, HHS' Office Of Inspector General says in a report released Friday (March 27).

Stakeholders clashed Friday (March 27) at a public meeting over FDA's proposed rule that would require generic drug makers update their labels independently as they discover new safety information. supporters of the agency's proposal said generic manufacturers should be held to the same standards as their brand-name counterparts, and opponents said only FDA has the authority to make changes and different labels will confuse providers and patients.

Rep. Michael Burgess (R-TX) introduced a bill last week that calls for the Government Accountability Office to observe whether generic versions of nonbiologic complex drugs and biological products that fall under the temporary approval authority of the Food, Drug and Cosmetic Act, present significantly different challenges in meeting approval standards than challenges presented by generic drugs of small-molecule reference products.